Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give Bioventus a “Moderate Buy” consensus: Five of six covering firms rate the stock a buy, while one recommends holding it. The average 12-month price target is $16.80, above the reported share price of $14.37.
• Recent analyst updates were largely positive, including Canaccord Genuity raising its target to $19 and Craig Hallum maintaining a buy rating with an $18 target.
• Bioventus reported quarterly EPS of $0.22, matching estimates, on revenue of $153.21 million. Institutional investors own approximately 62.94% of the stock, and management provided fiscal 2026 EPS guidance of $0.75–$0.79.

Bioventus Inc. (NASDAQ:BVS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $16.80.

Several equities analysts recently issued reports on BVS shares. Weiss Ratings upgraded Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, August 6th. Canaccord Genuity Group increased their target price on shares of Bioventus from $15.00 to $19.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Craig Hallum restated a "buy" rating and issued a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Barrington Research set a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, August 17th.

Hedge Funds Weigh In On Bioventus

Several institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its position in shares of Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company's stock worth $41,000 after purchasing an additional 5,490 shares during the period. California State Teachers Retirement System grew its stake in Bioventus by 147.4% during the 2nd quarter. California State Teachers Retirement System now owns 6,174 shares of the company's stock worth $58,000 after buying an additional 3,678 shares during the last quarter. Prelude Capital Management LLC bought a new position in Bioventus during the 3rd quarter worth $74,000. Mercer Global Advisors Inc. ADV acquired a new stake in Bioventus in the third quarter worth $78,000. Finally, Brooklyn Investment Group acquired a new position in shares of Bioventus during the fourth quarter valued at $91,000. 62.94% of the stock is owned by institutional investors.

Bioventus Price Performance

Shares of BVS stock opened at $14.37 on Thursday. The firm has a market cap of $1.21 billion, a P/E ratio of 18.66, a P/E/G ratio of 1.74 and a beta of 0.65. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.69 and a quick ratio of 1.17. Bioventus has a 1-year low of $6.26 and a 1-year high of $15.89. The firm has a fifty day moving average of $12.71 and a two-hundred day moving average of $10.46.

Bioventus (NASDAQ:BVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.The firm had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts anticipate that Bioventus will post 0.79 earnings per share for the current fiscal year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source